Hikma has temporarily suspended the roll-out of its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) in the US, just a month after the product was approved and launched. The pause is linked with an amendment to the firm’s abbreviated new drug application over packaging controls.
Announcing that it had “temporarily paused” the launch of its generic, Hikma explained that “following the US Food and Drug...




